Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Join | Sign in
Home>Resources>Posters

  Posters

Automation of a Generic Fluorescence Methyltransferase Activity Assay
X. Amouretti, P. Brescia, P. Banks, G. Prescott, Meera Kumar

Epigenetic processes are attracting considerable attention in drug discovery as their fundamental roles in controlling normal cell development and contributions to disease states become more clearly defined. This work combines a fluorescence-based assay with liquid handling and dispensing instrumentation and a multi-mode reader which can be used to monitor the biological activity of the histone methyltransferase (HMT) G9a, a model system.

Modeling Disposition of Sotalol following Intravenous and Oral Administration in Healthy Adult Subjects
S. Ray Chaudhuri, V. Lukacova and W. S. Woltosz

Sotalol is a non specific adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmia. Its absorption, distribution and systemic PK or, collectively, ‘disposition’ was modeled and simulated using GastroPlus™ v7.0. Biopharmaceutical properties were obtained from in silico predictions and in vitro measurements.

Predicting hERG Potassium Channel Affinity with Artificial Neural Network Ensembles
Adam C. Lee, GrazynaFraczkiewicz, Robert Fraczkiewicz, Robert D. Clark and Walter S. Woltosz

Modeling hERG inhibition has gained significant popularity since 2005, when the FDA recognized the correlation between hERG inhibition and a prolonged QT interval by issuing guidance for the evaluation of new non-antiarrythmic drugs against the hERG channel.Long QT syndrome or LQTS is a risk factor for ventricular tachyarrhythmias and sudden death.

Predicting Sites of Metabolism with Artificial Neural Network Ensembles
Marvin Waldman, Robert Fraczkiewicz, JinhuaZhang, Robert D. Clark and Walter S. Woltosz

Hepatic first-pass metabolism of many drugs and pro drugs plays a key role in their oral bioavailability. The human cytochrome P450 enzymes are responsible for the metabolism of most drugs. Knowledge of likely sites of metabolic attack in a drug molecule can aid in designing out unwanted metabolic liabilities early on in the drug discovery process, as well as in the design of pro drugs where metabolic transformation is desired.

GALAS Modeling Methodology Applications In The Prediction Of Drug Metabolism Related Properties
Remigijus Didziapetris, Justas Dapkunas, Andrius Sazonovas and Pranas Japertas

Analytical identification of metabolites for a drug candidate is usually a time consuming and low-throughput task and is performed only at the later phases of drug development. Therefore the possibility to predict possible sites of human liver microsomal (HLM) metabolism using in silico techniques would be a very attractive feature for any medicinal chemist.

Effective Use of In-Silico Tools in Lead Optimization
Pranas Japertas, Andrius Sazonovas and Kiril Lanevskij

Of all the challenges facing medicinal chemists in general, one of the most significant must be transforming an active molecule into a viable drug. Lead optimization efforts are guided by a combination of factors, such as potency, ease of synthesis, patentability concerns, specific synthetic constrains of the interaction with the target, as well as the lead’s toxicity and ADME properties.

The LAB2LAB™Advantage
Dr Brian Everatt1 C.Chem., FRSC, Simon Tullett2

Lab2Lab is a novel approach to submitting and transporting samples for analysis across an entire site. Sample tubes are registered and methods selected, an ELN reference is assigned and the sample tube is placed into the “Sender”. The system transports the samples using low pressure compressed air and directs them to the most appropriate analytical instrumentation available. The analytical results are then automatically returned to the originators ELN.

QSAR Model of Regioselectivity of Metabolism in Human Liver Microsomes: Development, Validation, Comparison and Adaptation to Novel Compounds
Justas Dapkunas, Andrius Sazonovas and Pranas Japertas

Analytical identification of metabolites for a drug candidate is usually a time consuming and low-throughput task which is performed only in late drug development phases. Therefore the ability to predict possible sites of human liver microsomal metabolism using in silico techniques would be highly beneficial for any medicinal chemist.

Ensuring the Quality of Registered Compounds in a Drug Discovery Environment – A Multidisciplinary Approach
Ryan Sasaki and Tara Sinclair

Lexicon Pharmaceuticals have demonstrated that a practical automated verification system using HPLC, LC/MS, and 1D and 2D NMR can be implemented in an industrial/pharmaceutical environment. This system has proven to be robust, and provides added value to compound collection integrity and quality.

<< 5 6 7 8 9 10 11 >>
Showing Results 71 - 80 of 182
Scientific News
Are Chemical Safety Regulations Changing Your Laboratory?
GHS changes to country chemical regulations affect everyone.
Drugs that Activate Brain Stem Cells May Reverse Multiple Sclerosis
NIH-funded study identifies over-the-counter compounds that may replace damaged cells.
Allergy Drug Inhibits Hepatitis C in Mice
NIH study suggests alternative drug to treat virus.
Saccharin Shows Promise as Cancer Inhibitor
Researchers have found that the artificial sweetener can inhibit cancer cell growth.
Treating Canine Periodontal Disease
The class of compounds, designed to resolve inflammation, has potential to treat chronic disease in animals and humans.
‘Warhead’ Molecule Targets Deadly Bacteria
Boston college chemists target bacterial lipids to label deadly bacteria, spare healthy cells.
Garlic Could Aid Cystic Fibrosis Fight
A chemical in garlic kills bacteria that cause deadly infections in people with cystic fibrosis, University of Edinburgh research shows.
UGA Researchers Discover Potential Treatment for Drug-resistant Tuberculosis
Researchers have developed a new small molecule drug as a treatment against multi-drug resistant tuberculosis.
A Protein's Novel Role In Several Types Of Cancers Discovered
Stanford ChEM-H scientists are helping to develop a novel cancer therapy based on a new finding of a protein that inadvertently promotes cancer growth.
Cancer Treatment with KU Origins Enters Second Clinical Trial
Cleave Biosciences has begun a Phase 1 clinical trial to evaluate CB-5083.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters